These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 29109198)

  • 1. Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey.
    Burstein B; Altobelli KK; Williams K; Cannon CP; Pencina MJ; Sniderman AD; Thanassoulis G
    Circulation; 2017 Nov; 136(19):1860-1862. PubMed ID: 29109198
    [No Abstract]   [Full Text] [Related]  

  • 2. High-Quality Statin Trials Support the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines After the HOPE-3 Trial (Heart Outcomes Prevention Evaluation-3): MESA (The Multiethnic Study of Atherosclerosis).
    Mortensen MB; Budoff M; Li D; Nasir K; Blaha MJ; Sandfort V; Jose Rodriguez C; Ouyang P; Falk E
    Circulation; 2017 Nov; 136(19):1863-1865. PubMed ID: 28634218
    [No Abstract]   [Full Text] [Related]  

  • 3. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA.
    Mortensen MB; Falk E; Li D; Nasir K; Blaha MJ; Sandfort V; Rodriguez CJ; Ouyang P; Budoff M
    JACC Cardiovasc Imaging; 2018 Feb; 11(2 Pt 1):221-230. PubMed ID: 28624395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins.
    Ratchford EV; Martin SS
    Vasc Med; 2017 Oct; 22(5):442-445. PubMed ID: 28803537
    [No Abstract]   [Full Text] [Related]  

  • 5. Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial.
    Persell SD; Brown T; Lee JY; Shah S; Henley E; Long T; Luther S; Lloyd-Jones DM; Jean-Jacques M; Kandula NR; Sanchez T; Baker DW
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):560-6. PubMed ID: 26555123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing Guidelines for Statin Treatment in Canada and the United States.
    Hennessy DA; Bushnik T; Manuel DG; Anderson TJ
    J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26175357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers.
    Akhabue E; Rittner SS; Carroll JE; Crawford PM; Dant L; Laws R; Leo MC; Puro J; Persell SD
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28673901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin efficacy in primary CVD prevention might diminish with patient age.
    Fernández-Ruiz I
    Nat Rev Cardiol; 2019 Apr; 16(4):200. PubMed ID: 30783252
    [No Abstract]   [Full Text] [Related]  

  • 9. Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease.
    Thanassoulis G; Williams K; Altobelli KK; Pencina MJ; Cannon CP; Sniderman AD
    Circulation; 2016 Apr; 133(16):1574-81. PubMed ID: 26945047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry.
    Nanna MG; Navar AM; Wang TY; Mi X; Virani SS; Louie MJ; Lee LV; Goldberg AC; Roger VL; Robinson J; Peterson ED
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29739801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context.
    Al Rifai M; Blumenthal RS; Stone NJ; Schofield RS; Orringer CE; Michos ED; Heidenreich PA; Braun L; Birtcher KK; Smith SC; Nambi V; Grundy S; Virani SS
    Prog Cardiovasc Dis; 2021; 68():2-6. PubMed ID: 34371083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to improve statin prescription guidelines in low-risk patients?
    Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW
    Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths.
    Virani SS
    Tex Heart Inst J; 2013; 40(3):288-9. PubMed ID: 23914021
    [No Abstract]   [Full Text] [Related]  

  • 14. Validation of the 2016 USPSTF recommendations for primary cardiovascular prevention in a large contemporary cohort.
    Schonmann Y; Bleich O; Matalon A; Yeshua H
    Eur J Prev Cardiol; 2018 May; 25(8):870-880. PubMed ID: 29517367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Statins for Primary Prevention: Selection of Risk Threshold and Implications Across Race and Gender.
    Goyal A; Cooper HA; Aronow WS; Nagpal P; Yandrapalli S; Nabors CC; Frishman WH
    Am J Med; 2018 Oct; 131(10):1234-1237. PubMed ID: 29928863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study.
    Waheed S; Pollack S; Roth M; Reichek N; Guerci A; Cao JJ
    Atherosclerosis; 2016 Dec; 255():193-199. PubMed ID: 27693004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort.
    Bai JW; Boulet G; Halpern EM; Lovblom LE; Eldelekli D; Keenan HA; Brent M; Paul N; Bril V; Cherney DZ; Weisman A; Perkins BA
    Cardiovasc Diabetol; 2016 Jan; 15():14. PubMed ID: 26809442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latinos Based on Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).
    Qureshi WT; Kaplan RC; Swett K; Burke G; Daviglus M; Jung M; Talavera GA; Chirinos DA; Reina SA; Davis S; Rodriguez CJ
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28495699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Preventive-Pill Paradox: How Shared Decision Making Could Increase Cardiovascular Morbidity and Mortality.
    Diprose W; Verster F
    Circulation; 2016 Nov; 134(21):1599-1600. PubMed ID: 27881503
    [No Abstract]   [Full Text] [Related]  

  • 20. The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?
    van Staa TP; Smeeth L; Ng ES; Goldacre B; Gulliford M
    Heart; 2013 Nov; 99(21):1597-602. PubMed ID: 23735939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.